CDC vac­cine com­mit­tee votes unan­i­mous­ly to rec­om­mend Sanofi and As­traZeneca's RSV im­mu­niza­tion for ba­bies

The CDC’s vac­cine ad­vi­so­ry com­mit­tee unan­i­mous­ly rec­om­mend­ed Sanofi’s RSV shot for ba­bies on Thurs­day. New­borns and in­fants un­der 8 months of age should re­ceive the Bey­for­tus (nir­se­vimab) mon­o­clon­al an­ti­body in ad­vance of the RSV sea­son, the Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) an­nounced af­ter a 10-0 vote.

The com­mit­tee al­so rec­om­mend­ed Bey­for­tus im­mu­niza­tions for chil­dren aged 8 to 19 months who are at high­er risk for RSV and go­ing in­to a sec­ond sea­son, by the same 10-0 vote. The RSV sea­son typ­i­cal­ly be­gins in No­vem­ber and runs for five months through March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER